New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

ConferencepositiveLeqembiPositive

AI Analysis

Summary

Eisai presented clinical data at AAIC 2026 showing that Leqembi's subcutaneous autoinjector formulation demonstrates similar efficacy and safety to the IV formulation for early Alzheimer's disease. The data supports the subcutaneous formulation as a potential alternative delivery method.

Outcome Details

Subcutaneous autoinjector formulation demonstrated similar efficacy and safety to IV formulation in early Alzheimer's disease

Importance:6/10

Sentiment:

0.70

Leqembisubcutaneous formulationAlzheimer's diseaseAAIC 2026clinical data

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Biotech on July 13, 2026 4:08 AM

Read Original